Neumora Therapeutics IPO Presentation Deck
NMRA-NMDA: Novel Approach for the Treatment of Schizophrenia
Pharmacology
NMDA receptor hypofunction is a leading hypothesis
for the cause of schizophrenia. NMDA positive
allosteric modulators (PAMS) can selectively enhance
physiological NMDAR function, decrease network
hypersynchrony observed in schizophrenia and
improve symptoms.
Indication
Schizophrenia
Epidemiology
Estimated ~3 million patients in the U.S. with
schizophrenia¹
Status
Undergoing IND-enabling activities
Drug Profile
Oral, once-daily
Strong IP Protection
Expect exclusivity through 2044+, based on
composition of matter protection plus potential for
patent term extension
Strong Biological
Rationale
Glutamate is the
major excitatory
neurotransmitter in
the brain and
dysregulation is
believed to be a key
driver of
schizophrenia
Principal neuron
Synaptic
cleft
Post-synaptic
neuron
SZ PATHOLOGY
O GABA
Understimulated
GABA pathways
Pre-synaptic
neuron
O-Glutamate
Hypofunctional
NMDAR
In SZ, hypofunctional
NMDARS cause
excitatory/inhibitory
imbalance
- NMRA-NMDA
PAM
NMDA receptor-
dependent signaling
Positive allosteric
modulator of NMDAR
Dopamine
receptor
Endogenous pathways
Obstructed in disease
Drug impact
O- Dopamine
Overstimulated
dopamine pathways
Confidential
21View entire presentation